

FILED ENTERED
LODGED RECEIVED

FEB 07 2003

AT SEATTLE
CLERK U.S. DISTRICT COURT
WESTERN DISTRICT OF WASHINGTON
BY *[Signature]* DEPUTY

UNITED STATES DISTRICT COURT
WESTERN DISTRICT OF WASHINGTON
AT SEATTLE

IN RE PHENYLPROPANOLAMINE
(PPA) PRODUCTS LIABILITY
LITIGATION,

NO. MDL 1407

This document relates to:

Bowen v. Schering-Plough
Corp., No. C01-303R

Kamla v. GlaxoSmithKline
Corp., et al., No. C01-304R,

Wurz, et al. v. American Home
Products Corp., No. C01-306R

Anderson, et al. v. Bayer
Corp., No. C01-307R

French, et al. v.
Bristol-Myers Squibb Co.,
No. C01-308R

Turner, et al. v. Novartis
Corp., et al., No. C01-309R

ORDER DENYING PLAINTIFFS'
RENEWED MOTION FOR CLASS
CERTIFICATION PURSUANT TO
RULE 23(B)(3) FOR ECONOMIC
INJURY CLAIMS

I. BACKGROUND

Plaintiffs' claims stem from their purchase of medication containing phenylpropanolamine ("PPA"). The court outlined the essential history involved in plaintiffs' cases and the PPA multi-district litigation ("MDL") generally in previous orders, including one denying certification in these cases. See Order Denying Certif. at 2 (Sept. 4, 2002). It is enough to repeat

ORDER

Page - 1 -



MD 01 01407 000001409

cc: Counsel: BJR

1409

1 here that defendants, along with other entities responsible for
2 manufacturing and marketing PPA products, withdrew those products
3 from the market following a November 6, 2000 Food and Drug
4 Administration ("FDA") health advisory and concomitant request
5 for the voluntary removal of PPA-containing products from the
6 market. See, e.g., Decl. of Michael W. Hogue ("Hogue Decl."),
7 Ex. B (FDA public health advisory pointing to a recent study
8 reporting an association between PPA and hemorrhagic stroke,
9 recommending that consumers not use any products containing PPA,
10 and noting request for voluntary removal). As described in more
11 detail below, plaintiffs primarily seek economic relief based on
12 their continued possession of PPA-containing products as of
13 November 6, 2000.

14 The court previously denied certification upon finding
15 plaintiffs' failure to demonstrate satisfaction of Federal Rule
16 of Civil Procedure 23(b)(3). The court concluded that the laws
17 of each state of purchase would apply to the proposed nationwide
18 class and found that plaintiffs neither adequately demonstrated
19 the predominance of common issues of law, nor provided the court
20 with a trial plan suitable at the class certification stage. See
21 Order Denying Certif. at 14-17. The court later found that
22 plaintiffs only belatedly provided, in their motion for reconsid-
23 eration, some of the arguments and information the court found
24 lacking in the class certification briefing. See Order Denying
25 Recons. at 3-4 (Sept. 26, 2002).

26 In the renewed motion for class certification currently

1 before the court, plaintiffs further address the court's concerns
2 relating to state law variations and submit a trial plan. They
3 also address superiority-related issues the court raised in
4 granting plaintiffs leave to file the renewed motion for class
5 certification, along with the remaining requirements of Rule 23.

6 II. CLASS ALLEGATIONS

7 Plaintiffs seek class certification in six different PPA
8 cases, each brought against a different defendant. They propose
9 the following class:

10 Consumers (excluding those who assert personal injury
11 claims and excluding residents of California) who
12 purchased and still possessed unused portions of non-
13 expired PPA products as of November 6, 2000, the date
of defendants' voluntary PPA product withdrawal (or
thereafter, in the event PPA products were sold after
the November 6, 2000 withdrawal).¹

14 They seek refunds for class members under theories of unjust
15 enrichment and breach of implied warranty. Each class would
16 break down into at least three subclasses, including an unjust
17 enrichment subclass, an implied warranty/privity subclass, and an
18 implied warranty/non-privity subclass.

19 Class members claim they purchased an unmerchantable product
20 and suffered economic injury in the amount of the price of the
21 unused portion of the product possessed as of November 6, 2000.
22 They seek a refund or disgorgement of defendants' profits through
23 restitution, the establishment of a fund supporting a medical

24
25 ¹ Plaintiffs exclude California residents because of similar
26 litigation brought in California state court. See Webster v.
Whitehall-Robins, et al., No. JCCP-4166.

1 research, education, and notification program, and injunctive
2 relief in the form of notice to consumers still in possession of
3 PPA-containing products.

4 The approximate size of the proposed class is unknown.

5 However, from a PPA over-the-counter ("OTC") cough, cold, and flu
6 product market totaling some \$440 million, plaintiffs proffer a
7 value of unused PPA-containing product possessed by consumers on
8 November 6, 2000 numbering in the tens of millions of dollars.
9 From that total, putative class members seek refunds averaging in
10 the range of \$3.00 per product.²

11 III. DISCUSSION

12 Federal Rule of Civil Procedure 23 governs class actions.
13 Plaintiffs, as the party seeking class certification, bear the
14 burden of demonstrating that they meet each of the four require-
15 ments of Rule 23(a) and at least one of the requirements of Rule
16 23(b). Zinser v. Accufix Research Inst., Inc., 253 F.3d 1180,
17 1186, amended by 273 F.3d 1266 (9th Cir. 2001). A trial court
18 must conduct a "'rigorous analysis'" in order to determine
19 whether the party seeking class certification satisfies the
20 prerequisites of Rule 23. Valentino v. Carter-Wallace, Inc., 97

21
22 ²Defendants reach this refund amount by interpreting the
23 estimates in the declaration of Dr. Sivaramakrishnan Siddarth,
24 plaintiffs' expert in the New Jersey PPA litigation, offered by
25 plaintiffs here in support of class certification. See Decl. of
26 Keelyn M. Friesen ("Friesen Decl."), Ex. 21. Plaintiffs note
that this amount assumes a \$5.00 average price of product, but do
not otherwise object to defendants' conclusion with respect to
the estimated average refund amount.

1 F.3d 1227, 1233 (9th Cir. 1996) (quoting In re: American Med.
2 Sys., Inc., 75 F.3d 1069, 1078-79 (6th Cir. 1996)). The trial
3 court possesses broad discretion on the question of class certif-
4 ication, but must exercise that discretion within the framework
5 of Rule 23. Zinser, 253 F.3d at 1186.

6 Plaintiffs seek certification pursuant to Rule 23(b)(3).
7 Rule 23(b)(3) allows for class certification where "the court
8 finds that the questions of law or fact common to the members of
9 the class predominate over any questions affecting only individ-
10 ual members, and that a class action is superior to other avail-
11 able methods for the fair and efficient adjudication of the
12 controversy." Fed. R. Civ. P. 23(b)(3). "Implicit in the
13 satisfaction of the predominance test is the notion that the
14 adjudication of common issues will help achieve judicial econ-
15 omy." Valentino, 97 F.3d at 1234. "Where classwide litigation
16 of common issues will reduce litigation costs and promote greater
17 efficiency, a class action may be superior to other methods of
18 litigation." Id.

19 Plaintiffs assert that, outside of privity - which they
20 account for through the above-described subclassing plan, no
21 material variations in state unjust enrichment and breach of
22 implied warranty laws exist as applied to the facts of the
23 proposed class. They assert the predominance of common facts
24 given that their claims relate to one product, and their evidence
25 commonly lies in the November 6, 2000 FDA advisory and defen-
26 dants' product withdrawal. However, even assuming relative

1 uniformity in state laws and the ability to avoid individualized
2 factual inquiries in establishing breach of warranty and unjust
3 enrichment, the court finds the proposed class unsuitable for
4 certification under Rule 23(b)(3).

5 A. Factors Relevant to Rule 23(b)(3) Predominance and Superior-
6 ity Analysis:

7 Rule 23(b)(3) identifies a list of factors pertinent to the
8 class certification analysis:

9 (A) the interest of members of the class in individu-
10 ally controlling the prosecution or defense of separate
11 actions; (B) the extent and nature of any litigation
12 concerning the controversy already commenced by or
13 against members of the class; (C) the desirability or
14 undesirability of concentrating the litigation of the
15 claims in the particular forum; (D) the difficulties
16 likely to be encountered in the management of a class
17 action.

18 Fed. R. Civ. P. 23(b)(3). These factors are not exhaustive.

19 Kamm v. California City Dev. Co., 509 F.2d 205, 212 (9th Cir.

20 1975). Ultimately, consideration of relevant factors "requires
21 the court to focus on the efficiency and economy elements of the
22 class action so that cases allowed under subdivision (b)(3) are
23 those that can be adjudicated most profitably on a representative
24 basis.'" Zinser, 253 F.3d at 1190 (quoting 7A Charles Alan

25 Wright, Arthur R. Miller & Mary Kay Kane, Federal Practice and
26 Procedure § 1780 at 562 (2d ed. 1986)).

Considering the minimal recovery available to individual
class members in isolation, the first Rule 23(b)(3) factor may be
said to weigh in favor of certification. See id. ("Where damages
suffered by each putative class member are not large, this factor

weighs in favor of certifying a class action.")³ Plaintiffs also arguably selected the most desirable forum for a nationwide class action given that this court also serves as the MDL court for all federal PPA cases. However, the court finds that considerations of manageability, the minuscule individual recoveries in comparison to the significant manageability problems, the extent and nature of litigation already commenced, and the existence of alternative remedies argue strongly and persuasively against certification.

1. Manageability:

The manageability determination "encompasses the whole range of practical problems that may render the class action format inappropriate for a particular suit." Eisen v. Carlisle & Jacquelin, 417 U.S. 156, 164 (1974). Here, the court finds that individualized factual inquiries required for identification of the proposed class would render this case unmanageable. See, e.g., Zinser, 253 F.3d at 1189, 1192 ("If each class member has to litigate numerous and substantial separate issues to establish his or her right to recovery individually a class action is not 'superior'."); O'Connor v. Boeing N. Am., Inc., 197 F.R.D. 404, 415 (C.D. Cal. 2000) ("'[A] class action is improper where an individual class member would be compelled to try numerous and substantial issues to establish his or her right to recover individually, after liability to the class is established.'")

³ But see infra part A.2.

1 (quoting earlier opinion at 184 F.R.D. 311, 340 (C.D. Cal.
2 1998)). The court also finds that plaintiffs' proposal for the
3 adoption of a fluid recovery procedure would not rectify this
4 manageability problem.

5 a. Class Identification:

6 It is axiomatic that a "class" must exist in order for a
7 class action to be certified. Simer v. Rios, 661 F.2d 655, 669
8 (7th Cir. 1981). As stated by the Seventh Circuit:

9 Identification of the class serves at least two obvious
10 purposes in the context of certification. First, it
11 alerts the court and parties to the burdens that such a
12 process might entail. In this way the court can decide
13 whether the class device simply would be an inefficient
14 way of trying the lawsuit for the parties as well as
15 for its own congested docket. Second, identifying the
16 class insures that those actually harmed by defendants'
17 wrongful conduct will be the recipients of the relief
18 eventually provided.

19 Id. at 670. "If the members of the class are not identifiable,
20 managing of the action may pose insurmountable problems." 5
21 James Wm. Moore et al., Moore's Federal Practice § 23.49[5][b]
22 (3d ed. 1997).

23 Here, individuals would be required to show some proof of
24 injury - in this case purchase and possession of a non-expired
25 PPA-containing product as of November 6, 2000 - in order to
26 qualify for membership in the proposed class. See Six Mexican
Workers v. Arizona Citrus Growers, 904 F.2d 1301, 1305 (9th Cir.
1990) (Rule 23 does not permit "dispensing with individual proof
of damages.") (citing In re Hotel Tel. Charges, 500 F.2d 86, 89-
92 (9th Cir. 1974) ("[E]ach member of the class seeking recovery

1 would then be required to prove that he patronized the hotel
2 while the surcharge was in effect and that he absorbed the cost
3 of the surcharge.")); Sikes v. Teleline, Inc., 281 F.3d 1350,
4 1365 (11th Cir. 2002) ("[C]lass treatment may not serve to lessen
5 the plaintiffs' burden of proof."), cert. denied 123 S.Ct. 117
6 (2002). Plaintiffs propose a proof of claim process in which
7 class members supply either physical proof of purchase and
8 possession, such as the actual product, product packaging, or a
9 receipt, or submit a certified oath or verification attesting to
10 purchase and possession as of November 6, 2000.

11 Plaintiffs posit that the only relevant question concerning
12 their proposal would be whether or not adequate checks for fraud
13 exist at the claims processing stage. However, the court finds
14 itself equally, if not more, concerned with the vagaries of
15 memory. Six out of the eight total putative subclass representa-
16 tives do not possess any physical proof that they purchased and
17 possessed a PPA-containing product as of November 6, 2000.⁴

19
20 ⁴See Pls.' Renewed Mot. at n. 8-9 (only Loretta Anderson and
21 Traci McKee have physical proof of purchase, through a product
22 and receipts respectively). Plaintiffs do not mention the
23 continued participation of three other previously named
24 plaintiffs, none of whom possess proof of purchase. See Decl. of
25 D. Joseph Hurson ("Hurson Decl."), Ex. J (the only product
26 possessed by Kristin Wurz consists of a bottle with a 1999
expiration date); Bristol-Myers Squibb Opp'n Class Certif. at 3-4
(Apr. 12, 2002) (packaging produced by Nancy French in deposition
indicated that the product did not contain PPA); and Defs.' Joint
Mem. Opp'n Class Certif. at 9 (Apr. 12, 2002) (Amanda Turner
lacks any proof she possessed a PPA product as of November 6,
2000).

1 Therefore, using the named plaintiffs as a marker, only a quarter
2 of the class, at most, would likely possess any physical proof of
3 purchase. A determination as to the remainder of the class would
4 rely on the memories of those individuals as to the types,
5 amounts, and expiration dates of medication they possessed over
6 two years ago. See, e.g., Webster v. Whitehall-Robins, et al.,
7 No. JCCP-4166, slip op. at 8 (Cal. Sup. Ct. Aug. 23, 2002)
8 (finding identical class proposed in California "not ascertain-
9 able": "The court would have to conduct an individualized inquiry
10 into several factors. Common to all of these questions is the
11 need to depend on human memory. The court doubts that many
12 individuals will still have records of minor purchases such as
13 these products dating back to the fall of 2000. People will have
14 to recall when they bought a product, when they used it, and how
15 much if any was left over on November 6, 2000. It will be a rare
16 person who has such a precise memory or who is so well organized.
17 Most likely, identifying this class will be a hit or miss propo-
18 sition.") (internal footnote omitted).⁵

19
20 ⁵ See also Sias v. Edge Communs. Inc., 8 P.3d 182, 185-189
21 (Okla. Civ. App. 2000) (upholding finding that identification of
22 class of prepaid calling card purchasers would be very difficult
23 and class adjudication unduly burdensome where class size would
24 be very substantial, defendant produced several different designs
25 of calling cards, and purchasers generally discarded cards after
26 use); Hayna v. Arby's, Inc., 425 N.E.2d 1174, 1183-89 (Ill. App.
Ct. 1981) (finding "insubstantial recoveries by class members,
high administrative costs in relation to aggregate recovery and
difficulty in corroborating claims[] valid considerations in
determining whether a class action is manageable[,] in reviewing
trial court's denial of certification of class of Illinois
purchasers of Arby's roast beef sandwiches). A number of federal

1 The ability to recollect these facts is complicated by not
2 only the ubiquitous nature of consumer OTC medication purchases,
3 but also by the fact that not all of the OTC products manufac-
4 tured and marketed by defendants contained PPA. Even within
5 various well-known brand names, such as "Contac," "Dimetapp," and
6 "Triaminic," only certain formulations actually contained PPA.
7 See Defs.' Joint Opp'n at 29-30 n. 20 (also noting that two-
8 thirds of "Coricidin" brand medications did not contain PPA).
9 Putative class members would be asked to distinguish, now over
10 two years after the fact, between defendants' various products
11 and the various formulations of those products, many of which
12 differed only slightly in name and packaging.⁶ Making matters
13 more difficult, some retailers apparently mimicked defendants'

14 _____
15 courts have denied class certification upon finding the class not
16 identifiable or ascertainable. These decisions typically rest on
17 the fact that identification of class members would require
18 inquiry into an individual's state of mind. See, e.g., Simer,
19 661 F.2d at 671, 673-74; Schwartz v. Upper Deck Co., 183 F.R.D.
20 672, 679 (S.D. Cal. 1999). Although the proposed class entails
21 identification problems of a different nature, it shares with
22 these cases the very real problem posed by a class requiring the
23 individualized adjudication of each potential class member's
24 claim.

25 ⁶For example, four Triaminic products contained PPA prior to
26 November 2000, including Triaminic Cough (formerly known as
(f/k/a) Triaminic DM), Triaminic Cold & Allergy (f/k/a Triaminic
Syrup), Triaminic Cold & Cough (formerly known as Triaminicol),
and Triaminic Chest Congestion (f/k/a Triaminic Expectorant),
while a number of Triaminic products never contained PPA,
including Triaminic A.M. (now called Triaminic Allergy
Congestion), Triaminic Cold Cough & Fever, Triaminic Cough &
Congestion, Triaminic Cold & Night Time Cough, and Triaminic
Cough & Sore Throat. Decl. of Henry Weidmuller, ¶7 (Apr. 12,
2002).

ORDER

Page - 11 -

1 packaging for their "house brands" of defendants' products, the
2 possession of which would presumably not qualify an individual
3 for class membership.

4 As such, the proposed class relates not to a single OTC
5 "product," as plaintiffs suggest, but to a single ingredient
6 contained in some OTC products. Except perhaps for those indi-
7 viduals who could attest to having reviewed the list of ingredi-
8 ents on a product of defendants in their possession in November
9 2000, the identification process would be fraught with uncer-
10 tainty. In fact, the risk of confusion would remain even for
11 those individuals who did read the small print, given that many
12 of defendants' products and formulations contained an alternative
13 ingredient, denominated "pseudoephedrine," which could be reason-
14 ably confused with PPA. See Hogue Decl., Ex. C, tab 88 (Los
15 Angeles Times article reporting that reading labels to make sure
16 PPA is not an ingredient "may be harder than it sounds" and
17 quoting a local pharmacist: "Many people get [PPA] confused with
18 pseudoephedrine, the alternative compound[.] 'They are both long
19 words[.]and 99% of the people don't know how to pronounce either
20 one.'")

21 Moreover, class identification and damages distribution
22 would not end with a determination as to the ingredient pos-
23 sessed. As noted, class members would also have to recall how
24 much, if any, of the product remained as of November 6, 2000, as
25 well as the product's expiration date. As with product identifi-
26 cation, given the passage of two years time, these details would

ORDER

1 sorely tax putative class members' memories.

2 The court does not believe the use of sworn oaths or affida-
3 vits would avoid individualized inquiry into class membership.
4 For example, one of the named plaintiffs, Terry Asbert, could not
5 recall in her deposition the formulations of the various brand
6 name medications she possessed in November 2000, nor the amount
7 remaining in her possession as of that date. Hurson Decl.,
8 Ex. B (when asked how she could determine which products did and
9 did not contain PPA, Asbert replied: "Oh, I don't know. That
10 would be hard.") Another named plaintiff, Traci McKee, admitted
11 confusion in identifying the types of Triaminic she purchased
12 over the years stemming from the various "alpha letters" that
13 appeared on the different formulations. Id., Ex. G.⁷ At one
14 point in her deposition, named plaintiff Deborah Kamla conceded
15 she did not know whether the Contac medication she purchased
16 contained PPA. Id., Ex. E. Additionally, a recent survey
17 respondent claimed to have purchased a "Chlor-Trimeton" product
18 containing PPA within the past two or three years, despite the
19 fact that those products have not contained PPA since 1997. See
20 Defs.' Jt. Opp'n at 30 n.20.

21 It is unrealistic to suppose that defendants will accept
22 sworn oaths or affidavits under these circumstances. Indeed, the
23 court would not expect them to do so. See, e.g., O'Connor, 197
24 F.R.D. at 415 (utilizing questionnaires at the claims stage
25

26 ⁷Given the many different formulations of this brand, see
supra n. 6, McKee's confusion is understandable.

1 eviscerated the role of the statute of limitations defense, which
2 was not based on "easily verifiable 'objective' criteria.";
3 noting the "futility of reliance on questionnaires [given the]
4 complex individualized inquiry" at issue); Thompson v. American
5 Tobacco Co., 189 F.R.D. 544, 554 (D. Minn. 1999) ("Plaintiffs
6 assume that the affidavits would constitute conclusive proof of
7 injury. In reality, even if a questionnaire could be used to
8 establish prima facie evidence of injury, Defendants would be
9 permitted to cross-examine each class members [sic] regarding
10 that alleged injury.")

11 Even individuals in possession of receipts would not be
12 immune from extensive inquiry. It is highly unlikely that, for
13 the rare person holding onto records of minor purchases made more
14 than two years prior, the receipts would contain enough detail to
15 allow a conclusion as to the precise product formulation pur-
16 chased and/or the date of expiration. Further, even if such
17 informative receipts existed, they would shed no light on the
18 amount of product, if any, remaining as of November 6, 2000.

19 Unlike cases involving substantial purchases for which proof
20 of purchase would be readily available or prescription medication
21 verifiable by medical and pharmacy records, the process of simply
22 identifying who rightfully belongs within the proposed class
23 would entail a host of mini-trials. The bulk of cases proffered
24 by plaintiffs involved class settlements in which defendants
25 agreed to class identification and damages distribution proce-
26 dures, and the courts were not faced with the reality of managing

ORDER

1 trials. See Amchem Prods., Inc. v. Windsor, 521 U.S. 591, 620
2 (1997) ("Confronted with a request for settlement-only class
3 certification, a district court need not inquire whether the
4 case, if tried, would present intractable management problems,[]
5 for the proposal is that there be no trial.") (internal citation
6 omitted). Moreover, the majority of non-settlement cases did not
7 entail the identification problems the court foresees here. See,
8 e.g., Long v. Trans World Airlines, Inc., 761 F. Supp. 1320, 1322
9 (N.D. Ill 1991) (class of former employees); Avery v. State Farm
10 Mut. Auto. Ins. Co., 746 N.E.2d 1242, 1255 (Ill. App. Ct. 2001)
11 (defendant maintained central database from which class members
12 could be identified); Naef v. Masonite Corp., No. CV-94-4033
13 (Ala. Cir. Ct. Nov. 15, 1995) (class members had brand of hard-
14 board siding installed on their homes) (attached as Ex. H to
15 Pls.' Compendium of Non-Reported Cases); Folbaum v. Rexall
16 Sundown, Inc., No. L-8625-98 (N.J. Super. Ct. Aug. 5, 2002)
17 (involving two specific vitamins produced and marketed by a
18 single company, and with a class limited to New Jersey residents)
19 (attached as Ex. E to Pls.' Compendium of Non-Reported Cases).
20 Because the vast majority of putative class members are unlikely
21 to possess proof of purchase, and given the purportedly immense
22 size of this class, the individualized inquiries surrounding
23 class identification would be prodigious and would defy the
24 court's ability to effectively and efficiently manage the litiga-
25
26

tion.⁸

b. Fluid Recovery:

As noted, plaintiffs propose that the court adopt a fluid recovery, or cy pres, procedure in this case. As explained by the Ninth Circuit:

When a class action involves a large number of class members but only a small individual recovery, the cost of separately proving and distributing each class member's damages may so outweigh the potential recovery that the class action becomes unfeasible. Fluid recovery or "cy pres" distribution avoids these difficulties by permitting aggregate calculation of damages, the use of summary claim procedures, and distribution of unclaimed funds to indirectly benefit the entire class.

Six Mexican Workers, 904 F.2d at 1305.

However, courts "have rejected fluid recovery as a 'solution of the manageability problems of class actions.'" Id. (quoting Eisen v. Carlisle & Jacquelin, 479 F.2d 1005, 1018 (2d Cir.

⁸Although the court finds the class identification problem significant enough, in and of itself, to prohibit the manageability of this litigation, additional complications are worthy of mention. For instance, the court would also be faced with computing individual damages. See, e.g., Schwartz, 183 F.R.D. at 680 (although differences in damage calculations for individual class members would not alone prevent class certification, court's decision was reinforced where "damages questions [were] layered onto the other issues of fact and law[.]"); see also 5 Moore's Federal Practice §23.49[5][b] ("[T]he presence of individual issues increases the difficulty of assessing injury and calculating damages.") Moreover, along with the potential for additional material state law variations, the breach of warranty and unjust enrichment claims could require individualized factual inquiries into issues such as causation, materiality, notice, and/or breach. Cf. In re Rezulin Prods. Liab. Litig., 210 F.R.D. 61, 68-69 (S.D.N.Y. 2002) (finding individual issues would predominate on a restitution of purchase price claim even in the absence of compensatory damages claims).

ORDER

Page - 16 -

1 1973), vacated on other grounds, 417 U.S. 156 (1974)). For
2 example, In re Hotel Tel. Charges involved antitrust allegations
3 based on a surcharge for telephone services imposed at a number
4 of different hotels nationwide. 500 F.2d at 88. The Ninth
5 Circuit rejected the use of fluid recovery as a means of dispens-
6 ing with proof of individual injury under Rule 23. Id. at 89-90.
7 See also Six Mexican Workers, 904 F.2d at 1305 (stating that the
8 court in Eisen, 479 F.2d at 1017-18, rejected a fluid recovery
9 procedure in an antitrust case where it "avoided constitutionally
10 required notice to each class member, dispensed with individual
11 calculation of damages, and distributed the damages to future
12 traders who were not necessarily members of the class.")

13 Plaintiffs distinguish their fluid recovery proposal from
14 these cases, asserting that it would be used only for the purpose
15 of distributing unclaimed, rather than unproven, damages. In
16 support, they point to the Ninth Circuit's holding in Six Mexican
17 Workers, allowing a cy pres distribution "for the limited purpose
18 of distributing unclaimed funds." Id. at 1305-06. Yet, plain-
19 tiffs ignore the fact that the individuals in Six Mexican Workers
20 sought damages under a statute which allowed damages not depend-
21 ent on proof of actual injury. Id. (plaintiffs sought statutory
22 damages under the Farm Labor Contractor Registration Act). In
23 other words, the only question at issue in that case was how to
24 distribute the damages awarded. Id. at 1307-09 (rejecting
25 distribution plan adopted because it did not adequately target
26 the class and failed to provide adequate supervision over the

1 distribution).

2 Here, the court's concerns lie in more than simply how to
3 distribute unclaimed damages. Instead, the court faces the
4 daunting task of determining who could claim those damages in the
5 first place. Given plaintiffs' supposition that tens of millions
6 of dollars are at stake, and the incredibly difficult and time
7 consuming process of distributing portions of that amount on an
8 individual basis, at approximately three dollars per product, the
9 adoption of a fluid recovery procedure would not serve to lessen
10 the manageability problems plaguing the proposed class.

11 2. Minimal Damages in Comparison to Manageability
12 Problems:

13 The court recognizes that, because of the small amount of
14 individual damages at issue, alternative methods to adjudication
15 by a class may be realistically lacking for individuals without
16 any proof of purchase. However, "the desirability of allowing
17 small claimants a forum to recover for largescale [] violations
18 does not eclipse the problem of unmanageability." In re Hotel
19 Tel. Charges, 500 F.2d at 90, 92 ("When, as here, there is no
20 realistic possibility that the class members will in fact receive
21 compensation, then monolithic class actions raising mind-boggling
22 manageability problems should be rejected.") Accord Thompson,
23 189 F.R.D. at 556 ("Although it is difficult to ignore th[e]
24 reality [that a class action is the only viable remedy for the
25 plaintiffs given the enormous burden of pursuing independent
26 litigation,] it is not a sufficient reason to 'headlong plunge

1 into an unmanageable and interminable litigation process.'")
2 (quoting Barreras Ruiz v. American Tobacco Co., 180 F.R.D. 194,
3 199 (D.P.R. 1998)).

4 As noted, class members here seek damages amounting to
5 approximately \$3.00 per product. Like the Ninth Circuit in In re
6 Hotel Tel. Charges, wherein putative class members stood to gain
7 refunds averaging \$2.20, the court finds this minimal recovery -
8 when considered in relation to the enormous costs in time,
9 effort, and burdens on the court - argues against the superiority
10 of class certification. See 500 F.2d at 88, 92 (reversing class
11 certification based on, inter alia, "the unmanageability of the
12 litigation in terms of time, administrative costs, and complex-
13 ity[, and] the minimal recovery it promises the potential indi-
14 vidual class members.")

15 3. Other Litigation Already Commenced:

16 As of the date of this order, almost 900 PPA-related per-
17 sonal injury actions have been transferred into this MDL. This
18 number does not account for the many state court cases, nor the
19 cases awaiting transfer into the MDL, nor even those not yet
20 filed in federal courts around the country. As such, to the
21 extent plaintiffs pursue a class vehicle as a means of punishing
22 defendants, preventing their retention of "ill gotten gains," or
23 deterring future behavior, the existing individual personal
24 injury lawsuits may well serve those purposes. See, e.g., In re
25 Rezulin Prods. Liab. Litig., 210 F.R.D. 61, 75 (S.D.N.Y. 2002)
26 ("If Rezulin and its marketing was as bad as plaintiffs claim,

1 defendants doubtless will get their comeuppance in the hundreds
2 or thousands of personal injury cases already pending against
3 them."); Webster, slip op. at 5 (rejecting deterrence as justifi-
4 cation for class certification given the multitude of state and
5 federal personal injury actions pending nationwide and the fact
6 that PPA-containing products are no longer being sold).

7 In contrast to the many personal injury actions filed, the
8 number of federal cases seeking economic damages is limited to
9 these plaintiffs.⁹ The court finds the lack of parallel, indi-
10 vidual suits significant. Clearly, denial of class certification
11 will not inundate the judicial system with individual claims.
12 See In re Hotel Tel. Charges, 500 F.2d at 91; Castano v. American
13 Tobacco Co., 84 F.3d 734, 747-48 (5th Cir. 1996). For these
14 reasons, the "litigation already commenced" factor argues against
15 the superiority of class certification in these cases.

16 4. Alternative Remedies:

17 Of course, the court retains the authority to limit and/or
18 redefine the proposed class to individuals possessing proof of
19 purchase and possession. Plaintiffs previously noted their
20

21 ⁹ Defendants draw the court's attention to one additional
22 case, and proposed class, purportedly limited to economic
23 recovery, which was transferred to this court in May 2002. See
24 Horne v. American Home Products Corp., No. C02-894R. They submit
25 that the court's order on plaintiffs' renewed motion for class
26 certification should also apply to Horne, despite the fact that
no motion for certification has been filed in that case. The
court only recently received plaintiffs' objections to this
request. Given the lack of complete briefing on this issue, the
court declines to extend this order to Horne.

1 continued interest in pursuing such a class in the event the
2 court denied the broader class proposed here. This limitation
3 would drastically reduce the number of individualized inquiries
4 associated with class identification, claims, and damages.
5 However, the court finds an already existing remedy presents an
6 additional barrier to this more limited class.

7 To this day, defendants maintain refund and product replace-
8 ment programs for individuals still in possession of PPA-contain-
9 ing products. It makes little sense to certify a class where a
10 class mechanism is unnecessary to afford the class members
11 redress. See, e.g., Chin v. Chrysler Corp., 182 F.R.D. 448, 462-
12 65 (D. N.J. 1998) (finding lack of superiority where reimburse-
13 ment available through recall program and through administrative
14 remedy); Berley v. Dreyfus Col., 43 F.R.D. 397, 398-99 (S.D.N.Y.
15 1967) (rejecting plaintiffs' proposal to "needlessly replace a
16 simple, amicable settlement procedure with complicated, pro-
17 tracted litigation" where the defendant offered a purchase price
18 refund to its customers); Webster, slip op. at 3 (finding the
19 fact that a class seeking refunds for PPA products "would not
20 produce any substantial benefit[,] given the defendants' refund
21 programs, to be the "most important reason" for denial of certifi-
22 cation).

23 Plaintiffs point to the limitations of these refund pro-
24 grams. For instance, several defendants require physical proof
25 of purchase such as bottle caps, packaging, and unused product in
26 order to qualify for a refund, while another does not specify the

1 type of proof required, while still another requires a "lot
2 code." Plaintiffs also make much of the fact that only one
3 defendant could identify a dollar amount refunded directly to
4 consumers, while many millions of dollars in refunds were pro-
5 vided to retailers. Additionally, plaintiffs describe the
6 programs as "silent," meaning that an individual must either
7 actively seek out a refund by directly contacting a defendant or
8 happen to run across a website on which the refund program might
9 be advertised.

10 However, the court finds proof of purchase requirements for
11 refund programs an extraordinarily commonplace practice amongst
12 retailers and, as evidenced by this opinion, a necessary require-
13 ment for class identification purposes. The fact that consumers
14 have not sought refunds in large numbers may well demonstrate
15 that certification of the proposed class would merely serve to
16 create lawsuits where none previously existed. See In re Hotel
17 Tel. Charges, 500 F.2d at 91. Moreover, the distinction between
18 the amount of refunds given to retailers, rather than consumers,
19 is likely due to the fact that the retailers had readily avail-
20 able proof of purchase in the form of the products themselves and
21 that retailers may be called upon by their customers to make
22 refunds.

23 Finally, although plaintiffs criticize the amount of public-
24 ity directly relating to defendants' refund and product replace-
25 ment programs, a significant number of people somehow heard about
26 these programs. In addition to the \$119,808 in refunds distrib-

1 uted to 14,000 consumers of Novartis products, American Home
2 Products and Bayer indicate receiving requests for refunds from
3 16,159 and 16,935 consumers respectively. See also Hurson Decl.,
4 Ex. EE (Fort Worth Star-Telegram article noting SmithKline
5 Beecham refund program). Also, a number of individuals may have
6 sought and received refunds from retailers of defendants' prod-
7 ucts. Id. (attaching newspaper articles indicating that retail-
8 ers, including Eckerd, Walgreens, and Wegmans stores, were
9 providing refunds to consumers). Moreover, the possible avail-
10 ability of refunds likely occurred to a number of people follow-
11 ing the widely publicized FDA advisory and product withdrawal.
12 See, e.g., Hogue Decl., Ex. B (FDA public health advisory);
13 Friesen Decl., Ex. 5 (FDA "Questions and Answers" web page: "[W]e
14 suggest you stop taking the drug [PPA] immediately and use an
15 alternative product."); Hogue Decl., Ex. C (attaching numerous
16 articles publicizing FDA advisory and product withdrawal," includ-
17 ing front page articles in major regional and national newspa-
18 pers); and id., Ex. G (attaching full-page advertisements run by
19 plaintiffs' lawyers in People and Time magazines).

20 While not all affected individuals sought refunds or re-
21 placement products, a substantial number of individuals and many
22 retailers clearly did, while hundreds, if not thousands, of PPA-
23 related personal injury cases have been filed in federal and
24 state courts. Plaintiffs do not persuade the court that a
25 nationwide class action would be superior to the remedy already
26 existing through these refund and product replacement programs.


ORDER

Page - 23 -

1 IV. CONCLUSION

2 For the reasons described above, the court finds that
3 plaintiffs fail to demonstrate satisfaction of Rule 23(b)(3). In
4 denying certification on this basis, the court does not find
5 consideration of the remaining Rule 23 requirements necessary.
6 Plaintiffs' renewed motion for class certification is hereby
7 DENIED.

8 DATED at Seattle, Washington this 7th day of February, 2003.

9 
10 BARBARA JACOBS ROTHSTEIN
11 UNITED STATES DISTRICT JUDGE
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26